Zydus Wins Appeal in Shire’s Patent Case Over Generic Lialda for UC

Zydus Wins Appeal in Shire’s Patent Case Over Generic Lialda for UC
Zydus Pharmaceuticals won a patent battle over Shire’s ulcerative colitis drug Lialda (mesalamine), with the U.S. Court of Appeals for the Federal Circuit ruling that Zydus’ proposed generic version of Lialda does not infringe upon Shire’s patent covering the drug. “We welcome this decision, which is a positive step and will help us further our mission

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *